Furthermore, although results from several retrospective and prospective studies did not show an increased risk of infection after IL-6 antagonist treatment in COVID-19 patients, the most common infections reported are represented by Gram-positive bacteremia [77,78], which occurred more often than Gram-negative bacteremia, fungemia, or viremia, [79,80]; Staphylococcus aureus was the more frequent causative organism [81]. This evidence concerns the gene IL6 and COVID-19.